Lethal Arg9Cys phospholamban mutation hinders Ca2+-ATPase regulation and phosphorylation by protein kinase A

The regulatory interaction of phospholamban (PLN) with Ca2+-ATPase controls the uptake of calcium into the sarcoplasmic reticulum, modulating heart muscle contractility. A missense mutation in PLN cytoplasmic domain (R9C) triggers dilated cardiomyopathy in humans, leading to premature death. Using a combination of biochemical and biophysical techniques both in vitro and in live cells, we show that the R9C mutation increases the stability of the PLN pentameric assembly via disulfide bridge formation, preventing its binding to Ca2+-ATPase as well as phosphorylation by protein kinase A. These effects are enhanced under oxidizing conditions, suggesting that oxidative stress may exacerbate the cardiotoxic effects of the PLNR9C mutant. These results reveal a regulatory role of the PLN pentamer in calcium homeostasis, going beyond the previously hypothesized role of passive storage for active monomers.

[1]  D. Stokes,et al.  Phosphorylation and mutation of phospholamban alter physical interactions with the sarcoplasmic reticulum calcium pump. , 2011, Journal of molecular biology.

[2]  E. McNally,et al.  The genetics of dilated cardiomyopathy , 2010, Current opinion in cardiology.

[3]  B. Wolska,et al.  Rescue of familial cardiomyopathies by modifications at the level of sarcomere and Ca2+ fluxes. , 2010, Journal of molecular and cellular cardiology.

[4]  Nathaniel J. Traaseth,et al.  Structure and topology of monomeric phospholamban in lipid membranes determined by a hybrid solution and solid-state NMR approach , 2009, Proceedings of the National Academy of Sciences.

[5]  Ferhaan Ahmad,et al.  Alterations of Phospholamban Function Can Exhibit Cardiotoxic Effects Independent of Excessive Sarcoplasmic Reticulum Ca2+-ATPase Inhibition , 2009, Circulation.

[6]  Christopher M. Pavlos,et al.  Phospholamban thiols play a central role in activation of the cardiac muscle sarcoplasmic reticulum calcium pump by nitroxyl. , 2008, Biochemistry.

[7]  Z. Hou,et al.  Phosphomimetic Mutations Increase Phospholamban Oligomerization and Alter the Structure of Its Regulatory Complex* , 2008, Journal of Biological Chemistry.

[8]  D. Bers,et al.  Phospholamban Oligomerization, Quaternary Structure, and Sarco(endo)plasmic Reticulum Calcium ATPase Binding Measured by Fluorescence Resonance Energy Transfer in Living Cells* , 2008, Journal of Biological Chemistry.

[9]  Andrew Emili,et al.  Comparative Proteomics Profiling of a Phospholamban Mutant Mouse Model of Dilated Cardiomyopathy Reveals Progressive Intracellular Stress Responses*S , 2008, Molecular & Cellular Proteomics.

[10]  D. Bers.  Calcium cycling and signaling in cardiac myocytes. , 2008, Annual review of physiology.

[11]  Nathaniel J. Traaseth,et al.  Allosteric cooperativity in protein kinase A , 2008, Proceedings of the National Academy of Sciences.

[12]  L. Masterson,et al.  Structural and Dynamic Basis of Phospholamban and Sarcolipin Inhibition of Ca2+-ATPase† , 2008 .

[13]  Shadi Abu-Baker,et al.  The structural topology of wild‐type phospholamban in oriented lipid bilayers using 15N solid‐state NMR spectroscopy , 2007, Protein science : a publication of the Protein Society.

[14]  N. Görmüs,et al.  Preconditioning With Levosimendan Prevents Contractile Dysfunction Due To H2O2-induced Oxidative Stress in Human Myocardium , 2007, Journal of cardiovascular pharmacology.

[15]  David D. Thomas,et al.  Spectroscopic validation of the pentameric structure of phospholamban , 2007, Proceedings of the National Academy of Sciences.

[16]  B. Funke,et al.  Dilated cardiomyopathy , 2007, Archives of Disease in Childhood.

[17]  A. Zima,et al.  Redox regulation of cardiac calcium channels and transporters. , 2006, Cardiovascular research.

[18]  D. Stokes,et al.  Interactions between Ca2+-ATPase and the pentameric form of phospholamban in two-dimensional co-crystals. , 2006, Biophysical journal.

[19]  W. Zipfel,et al.  Optimization of Pairings and Detection Conditions for Measurement of FRET between Cyan and Yellow Fluorescent Proteins , 2006, Microscopy and Microanalysis.

[20]  David D. Thomas,et al.  Phospholamban pentamer quaternary conformation determined by in-gel fluorescence anisotropy. , 2005, Biochemistry.

[21]  Gianluigi Veglia,et al.  Serine 16 phosphorylation induces an order-to-disorder transition in monomeric phospholamban. , 2005, Biochemistry.

[22]  T. Squier,et al.  Redox modulation of cellular signaling and metabolism through reversible oxidation of methionine sensors in calcium regulatory proteins. , 2005, Biochimica et biophysica acta.

[23]  J. Qian,et al.  Threonine-17 phosphorylation of phospholamban: a key determinant of frequency-dependent increase of cardiac contractility. , 2004, Journal of molecular and cellular cardiology.

[24]  T. Zal,et al.  Photobleaching-corrected FRET efficiency imaging of live cells. , 2004, Biophysical journal.

[25]  David D. Thomas,et al.  NMR solution structure and topological orientation of monomeric phospholamban in dodecylphosphocholine micelles. , 2003, Biophysical journal.

[26]  E. Kranias,et al.  Calcium: Phospholamban: a crucial regulator of cardiac contractility , 2003, Nature Reviews Molecular Cell Biology.

[27]  David D. Thomas,et al.  Defining the molecular components of calcium transport regulation in a reconstituted membrane system. , 2003, Biochemistry.

[28]  Ulrike Mende,et al.  Dilated Cardiomyopathy and Heart Failure Caused by a Mutation in Phospholamban , 2003, Science.

[29]  S. Dudley,et al.  Heart failure, oxidative stress, and ion channel modulation. , 2002, Congestive heart failure.

[30]  G. Patterson,et al.  Förster distances between green fluorescent protein pairs. , 2000, Analytical biochemistry.

[31]  D. D. Thomas,et al.  Synthetic null-cysteine phospholamban analogue and the corresponding transmembrane domain inhibit the Ca-ATPase. , 2000, Biochemistry.

[32]  D. Maclennan.  Ca2+ signalling and muscle disease. , 2000, European journal of biochemistry.

[33]  Solaro Rj.  Is calcium the 'cure' for dilated cardiomyopathy? , 1999 .

[34]  D. D. Thomas,et al.  Depolymerization of phospholamban in the presence of calcium pump: a fluorescence energy transfer study. , 1999, Biochemistry.

[35]  D. Bers,et al.  Pentameric Assembly of Phospholamban Facilitates Inhibition of Cardiac Function in Vivo * , 1998, The Journal of Biological Chemistry.

[36]  L. Jones,et al.  Phospholamban: protein structure, mechanism of action, and role in cardiac function. , 1998, Physiological reviews.

[37]  D. D. Thomas,et al.  Cysteine reactivity and oligomeric structures of phospholamban and its mutants. , 1998, Biochemistry.

[38]  D. Maclennan,et al.  Phospholamban Inhibitory Function Is Activated by Depolymerization* , 1997, The Journal of Biological Chemistry.

[39]  M. Le,et al.  A procedure for the determination of monothiols in the presence of dithiothreitol--an improved assay for the reduction of disulfides. , 1995, Analytical biochemistry.

[40]  A. J. Williams,et al.  Modification of the gating of the cardiac sarcoplasmic reticulum Ca(2+)-release channel by H2O2 and dithiothreitol. , 1994, The American journal of physiology.

[41]  T. Doetschman,et al.  Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. , 1994, Circulation research.

[42]  P. Singal,et al.  Pressure overload-induced cardiac hypertrophy with and without dilation. , 1992, Journal of the American College of Cardiology.

[43]  T. L. Hill,et al.  Equilibrium cooperative binding of calcium and protons by sarcoplasmic reticulum ATPase. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[44]  P. Cook.  Kinetic studies to determine the mechanism of regulation of bovine liver glutamate dehydrogenase by nucleotide effectors. , 1982, Biochemistry.

[45]  A. Guidotti,et al.  Endogenous protein kinase inhibitors. Purification, characterization, and distribution in different tissues. , 1977, The Journal of biological chemistry.

[46]  Lei Shi,et al.  Structural and dynamic basis of phospholamban and sarcolipin inhibition of Ca(2+)-ATPase. , 2008, Biochemistry.

[47]  D. Bers,et al.  Calcium and cardiomyopathies. , 2007, Sub-cellular biochemistry.

[48]  A. Nishiyama,et al.  Cardiac oxidative stress in acute and chronic isoproterenol-infused rats. , 2005, Cardiovascular research.

[49]  Michael D. Abràmoff,et al.  Image processing with ImageJ , 2004 .

[50]  C. Toyoshima.  Inaugural Article: Modeling of the inhibitory interaction of phospholamban with the Ca2+ ATPase , 2003 .

[51]  R. Solaro,et al.  Is calcium the 'cure' for dilated cardiomyopathy? , 1999, Nature Medicine.

[52]  S. Taylor,et al.  Prokaryotic expression of catalytic subunit of adenosine cyclic monophosphate-dependent protein kinase. , 1991, Methods in enzymology.

[53]  D. Stokes,et al.  Three-dimensional crystals of CaATPase from sarcoplasmic reticulum. Symmetry and molecular packing. , 1990, Biophysical journal.

[54]  A. Habeeb.  [37] Reaction of protein sulfhydryl groups with Ellman's reagent. , 1972, Methods in enzymology.

[55]  Th. Förster.  Zwischenmolekulare Energiewanderung und Fluoreszenz , 1948 .